Compare ResMed Inc. (RMD) vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $25.13 (market cap $156.97B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 4.9× ResMed Inc.'s market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays the higher dividend (2.34%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 1 Days on average.
| RMD | SMFG | |
|---|---|---|
Market Cap | $31.89B | $156.97B |
Volume | 618,314 | 1,237,125 |
Sector | Health | Financials |
52-Week High | $277.88 | $27.56 |
52-Week Low | $182.82 | $15.20 |
Typical Hold Time | 51 Days | 1 Days |
Enterprise Value | $31.24B | $12.48T |
Dividend Yield | 1.16% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →
